Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat The 3 Penny Stocks You Swore You'd Never Buy (But You'll Check Anyway)Authored by Chris Markoch. Article Published: 1/18/2026. 
In Brief - Vaxart is a clinical-stage biotech developing oral vaccines that could transform global immunization if its platform proves effective.
- Microvision develops cost-effective lidar technology for autonomous vehicles, with upside tied to industry adoption and potential partnerships.
- Datavault AI focuses on monetizing digital data through AI and blockchain tools, offering speculative exposure to the emerging data-as-an-asset theme.
Penny stocks attract speculative investors seeking high-risk, high-reward opportunities. These typically involve companies with disruptive technologies, exposure to an emerging trend, or compelling turnaround stories. Many will never scale, but if just one succeeds, investors can see outsized returns. For investors who believe strength lies in numbers, MarketBeat provides a tool that lists the 100 Most Popular Penny Stocks, ranked by the number of MarketBeat subscribers following each company. Popularity is no guarantee of success, but it can lend additional conviction to a trade. On September 14th, 2023, something big happened that didn't make the news. The price gap between London gold and Shanghai gold blew out to $120 an ounce. For years, that gap was a few dollars, maybe $5 or $10. A 20x jump in seconds isn't a glitch, it's the system breaking. Traders tried to buy gold in London to sell in Shanghai, but hit a wall. The London vaults were empty. Since that day, gold has hit 53 all-time highs. One stock is positioned to capture the bulk of this wealth transfer. See the full story on this opportunity now. Some investors use a $5-per-share cutoff when describing penny stocks. This screener, however, follows the traditional definition: stocks priced below $1. These names are highly volatile — do your own research and confirm your risk tolerance before opening positions. Vaxart: A Potential Game-Changer for Global Immunization Efforts Vaxart Inc. (NASDAQ: VXRT) is a clinical-stage biotechnology company developing oral vaccines for infectious diseases, including influenza, norovirus, and COVID-19. Unlike injected vaccines, Vaxart's tablet-based platform is designed to simplify distribution and improve global accessibility. The bull case for Vaxart rests on that innovative delivery approach. If the company secures FDA approval and successfully scales manufacturing and distribution, its oral vaccines could reduce logistical barriers to mass immunization and attract significant licensing partners. Positive trial readouts or a commercial collaboration could materially shift sentiment and valuation from the stock's current low base. Clinical risk is the biggest challenge: Vaxart has not yet brought a product to market, and vaccine development is expensive and unpredictable. Established competitors with deeper R&D budgets also limit visibility. For now, Vaxart is more of a long-term speculative bet on platform validation than a near-term profit story. MarketBeat analyst coverage for Vaxart is sparse — only a single analyst currently follows the name — which should give investors pause. Institutional ownership sits around 18%. On the positive side, short interest is only about 2%, which could limit at least one source of volatility. Microvision: Developing Cost-Effective LiDAR Units For Autonomous Driving Microvision Inc. (NASDAQ: MVIS) develops LiDAR (light detection and ranging) sensors used in autonomous vehicles, smart infrastructure, and industrial sensing. Its hardware and software enable precise 3D mapping needed for self-driving systems and advanced driver-assistance systems (ADAS). Microvision focuses on compact, cost-effective LiDAR units that could appeal to automakers seeking scalable sensor solutions. The bull case depends on the continued push toward vehicle automation and the company securing partnerships with large auto manufacturers. Demonstrating superior performance or cost advantages could lead to supply agreements or licensing deals that improve revenue visibility. Microvision's technology also has potential applications beyond automotive — in robotics and smart cities — which adds optionality. Still, competition is intense from LiDAR companies such as Luminar (NASDAQ: LAZR), Innoviz (NASDAQ: INVZ), and Ouster (NYSE: OUST). Commercial adoption of LiDAR has experienced delays, and the path to profitability remains uncertain — factors that have frustrated investors. MVIS is covered by three analysts and carries a consensus price target of $2.50, roughly a 169% premium to its Jan. 15 closing price. Like many speculative names, Microvision has relatively low institutional ownership (about 30%) and elevated short interest (around 21%), which can amplify volatility for long-term holders. Datavault AI: Trying to Democratize Data Ownership Datavault AI Inc. (NASDAQ: DVLT) operates at the intersection of artificial intelligence, data monetization, and digital asset management. The company helps organizations convert raw data into tradable, revenue-generating assets through its patented Datavault platform. By combining AI, blockchain, and analytics, Datavault AI aims to democratize data ownership and unlock monetization opportunities traditional systems may miss. The bullish thesis centers on a niche focus and scalability potential. As data becomes more valuable, businesses — and potentially individuals — are looking for secure ways to monetize digital information. Datavault's platform could benefit from broader AI adoption and growing interest in data sovereignty. Early traction or strategic partnerships could serve as catalysts for investor confidence. That said, Datavault AI operates in a highly experimental space. Its business model is still evolving and the path to meaningful revenue is unproven. Institutional ownership is under 1%, and short interest exceeds 16% at the time of writing. Investors considering DVLT should view it as a long-term, speculative position based on belief in data-as-an-asset innovation rather than on near-term earnings potential.
| 
